The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19 (original) (raw)
Related papers
Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
Stem Cell Reviews and Reports
COVID-19" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.
Mesenchymal stem cells and COVID-19
2020
With the appearance of the first cases of COVID-19 infection, which had a severe clinical picture accompanied by respiratory insufficiency, as well as multiorgan dysfunction, mesenchymal stem cells became the subject of intensive research. The main cause of tissue and organ damage in patients with COVID-19 infection is thought to be a cytokine storm, which is the result of an imbalance in the regulation of the host immune system. Previous studies have shown that mesenchymal stem cells have an immunomodulatory effect and can prevent and reduce the cytokine storm triggered by the SARS-Cov-2 virus. Numerous clinical studies on the use of mesenchymal stem cells in patients with a severe clinical picture of COVID-19 are underway. Undoubtedly, cell therapy could be of great importance in the treatment of patients with a severe clinical picture of COVID-19, but it takes time to consider the efficacy and safety of such therapy, which is possible only through controlled multicenter clinical ...
Mesenchymal Stem Cell Therapy For COVID-19; Is A New Challenge Review
International Journal of Progressive Sciences and Technologies, 2021
Coronavirus" is the word that absolutely isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID19, as a pandemic, has driven numerous researchers from various biomedical fields to discover arrangements or therapies to deal with the pandemic. Nonetheless, no standard treatment for this infection has been found to date. Presumably, preventing the acute severe respiratory infection type of COVID-19 as the most risky period of this disease can be useful for the therapy and decrease of the death rate. In such manner, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a reasonable restorative methodology and a several clinical studies have started. Recently, MSCs as indicated by their immunomodulatory and regenerative properties stand out in clinical trials. After the intravenous transplantation of MSCs, a large population of cells gathers in the lung, which they close by immunomodulatory impact could protect alveolar epithelial cells, recover the respiratory microenvironment, prevent pneumonic fibrosis, and cure lung dysfunction. Given the vulnerabilities here, we checked on detailed clinical preliminaries and theories to give helpful data to scientists and those keen on stem cell therapy. In this study, we considered this new way to deal with improve patient's immunological reactions to COVID-19 utilizing MSCs and talked about the parts of this proposed treatment. Nonetheless, right now, there are no affirmed MSC-based methodologies for the anticipation or potentially treatment of COVID-19 patients however clinical preliminaries progressing. Keywords-(COVID-19, Mesenchymal stem cells, stem cell treatment, Immunomodulatory, Clinical trials). I. INTRODUCTION At the long term's end, various instances of extreme respiratory infections were reported for in Wuhan, China, and were at first idea to be an occasional influenza sickness, given that some patients had a history of attending or working in the wholesale market for fish and seafood , then the market was promptly closed down on January 1, and environmental sanitation and disinfection were completely executed. A couple of days after the fact, subsequent to dismissing the analysis of occasional flu, avian flu, adenovirus, Covid, SARS, Covid, and other organisms, on Jan. 1, the infection was proclaimed a causative agent of the disease in four of the nine hospitalized patients: another Covid that has a 5% genetic relationship with SARS and is a subset of Sarbecovirus [1]. As of
Potential therapeutic application of mesenchymal stem cells in COVID-19 complications
Medycyna Pracy
Mesenchymal stem cells (MSCs) have remarkable immunomodulatory properties, low immunogenicity, and paracrine properties as well as the ability to differentiate into multiple cell lines. These properties make them potential candidates for clinical applications in the treatment of neurodegenerative, cardiovascular, and lung diseases, which may be occupational diseases. Preclinical studies using experimental animal models have demonstrated regenerative properties of MSCs in diseases such as silicosis and occupational asthma. Currently, treatment of the novel disease COVID-19 could be enhanced by using MSC therapies. This disease affects many professional groups with great intensity and its consequences might be considered as an occupational disease. It is a significant public health problem and a therapeutic challenge. Despite the development of vaccines against COVID-19, there is growing concern about the emergence of new mutations of the SARS-CoV-2 virus in addition to the known alpha, beta, gamma, and delta variants. There is still no effective COVID-19 treatment and the existing ones only play a supporting role. MSCs offer treatment possibilities as an alternative or complementary therapy. The clinical trials to date using MSCs in patients with COVID-19 give hope for the safe and effective use of this stem cell population. Med Pr. 2021;72(6)
Use of Mesenchymal Stem Cells in COVID-19
2020
Since the start of the coronavirus SARS-CoV2 (COVID-19) outbreak in China, in the end of 2019, the virus has rapidly spread throughout the World, causing a path of destruction behind it, with mortality figures exceeding 7.000.000 globally, and a death toll reaching numbers of over 400.000. Economically, the pandemic has been estimated to cause a Worldwide crise similar or worse than World War II. While physians are just barely able to cope with the amount of patients, lack of knowledge on the pathogenesis of the disease, its targets and possible effective treatments are major hurdles in the design of proper treatment strategies. Current treatment options using a variety of anti-viral, anti-bacterial and other drugs, have shown to be often insufficient and in severe cases of COVID-19 disease, the use of stem cells, and in particular mesenchymal stem cells, has been proposed as auxiliary treatment, based on their proven capacity for potent immunomodulation and tissue regeneration. Here, we provide a brief overview of current data on the use of MSCs for treatment of COVID-19.
Mesenchymal Stem Cell as a Successful Therapy for COVID-19 Patient: Systematic Review
Biosaintifika: Journal of Biology & Biology Education
COVID-19 has been declared a pandemic and continues to spread, leading to health and economic problems and economic burdens worldwide. COVID-19 symptoms are similar to the flu and, in severely infected patients, emerge as an acute respiratory syndrome (ARDS), pulmonary fibrosis, edema, and even organ failure. These are due to an imbalanced immune response with a more severe effect than the virus attack. However, no specific medications and treatments are available in dealing with the COVID-19. Hence, mesenchymal stem cell (MSC) treatment is proposed as one therapeutic approach. The MSCs can produce growth factors and immune protective cytokines that could fight viral infection and are proven to help endothelial cell repair. These capabilities are expected to help resist viruses and tissue repair in a patient body. MSC is believed to prevent acute respiratory infections, the most dangerous stage of COVID-19 pathogenesis. In this study, we collect some literature, reviewing and summar...
Molecular and Cellular Biomedical Sciences
Recent research has demonstrated that mesenchymal stem cells (MSCs) potentially benefit and enhance coronavirus disease (COVID-19) recovery. This benefit occurs via a mechanism that promotes viral clearance by phagocytes and macrophages. This action occurs through the innate (increase in IL-10 production and decrease in TNF-α and IL-12 production) and the adaptive immune system (decrease in IL-17 production, promote regulatory T cell proliferation and inhibit effectors T cell proliferation). MSCs are expected to act as an anti-inflammatory in the hyper-inflammatory state of COVID-19. MSCs enhance immune cell replacement that have been overwhelmed or have been lost due to cytokine storm. Although vaccines are the answer to this pandemic, MSCs can improve COVID-19 patients, especially in patients with chronic illnesses. The focus on keeping death-rates low is a great opportunity for MSCs-based therapy for severe or critically ill patients. MSCs and conditioned medium have the potentia...
Advanced Pharmaceutical Bulletin, 2021
After SARS and MERS outbreaks, COVID-19 is the third coronavirus epidemic that soon turned into a pandemic. This virus causes acute respiratory syndrome in infected people. The mortality rate of SARS-CoV-2 infection will probably rise unless efficient treatments or vaccines are developed. The global funding and medical communities have started performing more than five hundred clinical examinations on a broad spectrum of repurposed drugs to acquire effective treatments. Besides, other novel treatment approaches have also recently emerged, including cellular host-directed therapies. They counteract the unwanted responses of the host immune system that led to the severe pathogenesis of SARS-CoV-2. This brief review focuses on Mesenchymal stem cell (MSC) principles in treating the COVID-19. The US clinical trials database and the world health organization database for clinical trials have reported 82 clinical trials (altogether) exploring the effects of MSCs in COVID-19 treatment. MSCs...
Mesenchymal Stem Cells Impact on COVID-19 Patients Immune System, an Ex Vivo Study
2021
Current clinical management approaches for COVID-19 patients are generally based on supportive treatment, which mainly includes respiratory support and restricted fluid input, which is currently a subject of much debate. Systemic Inflammation caused by SARS-CoV-2 may be related to various extrapulmonary comorbidities such as cytokine-mediated neuroinflammation leading to both non-neuronal and neurological consequences in COVID-19. Mesenchymal stem cells (MSCs) are adult stem cells with multipotent properties suitable for medical applications that have been reported as potential therapies in the setting of lung diseases. The immunosuppressive properties of MSCs provide a strong rationale to explore their potential beneficial effects on immune events in COVID-19. Multiple in vivo studies have demonstrated the capability of MSCs to prevent inflammatory responses and reduce lung damage. Recently, the use of MSCs in treating COVID-19 disease has improved long-term pulmonary function, but...